Heart valve disease management represents an unmet clinical need. Studies have shown that valve disease has an increasing incidence with age, dramatically spiking after age 65.
There is an overall prevalence of 2.5% for any valve disease. Bicuspid aortic valve disorder is the most common cardiovascular defect. Patients who have valve disease have a 79% survival rate at five years and 68% at eight years following diagnosis. Patients without valve disease have a 93% survival rate and 86% survival rate and five and eight years, respectively.
The Heart Valve Translational Research Program (HVTRP) at Brigham and Women’s Hospital (BWH) was developed to find treatments to cure heart valve diseases through innovative, multidisciplinary research.
To address the complexities of valve diseases and expedite new treatment options, we have assembled a multidisciplinary team from departments throughout BWH. The team approach allows us to:
The goals of the Heart Valve Translational Research Program are to:
For over a century, a leader in patient care, medical education and research, with expertise in virtually every specialty of medicine and surgery.